In accordance with the literature, most vaccines against respiratory viruses, such as COVID-19, are administered, in general, intramuscularly in order to elicit a robust systemic immune response, which includes higher IgG levels, and not a protective immunity on the mucosa of the upper airways, mainly by secretory IgA, as can be developed after natural infection by the respiratory virus [46]. Here, CD79A is linked to COVID-19.